Clinical trial / 2004
In patients with Parkinson's disease, 30 g of Mucuna pruriens seed powder showed faster onset and longer on-time compared to standard levodopa/carbidopa.
Eight Parkinson's disease patients completed a randomized, double-blind crossover trial challenging them with single doses of 200/50 mg L-dopa/carbidopa (LD/CD) and 15 g and 30 g of Mucuna pruriens preparation at weekly intervals. Compared with standard LD/CD, the 30 g mucuna dose led to a significantly faster onset of effect (34.6 vs 68.5 min; p = 0.021) and a 21.9% (37 min) longer mean on-time (p = 0.021). Peak L-dopa plasma concentrations were 110% higher and the area under the curve was 165.3% larger (p = 0.012) with 30 g mucuna. No significant differences were observed in dyskinesias or tolerability.
- Study type
- Randomized, controlled, double-blind crossover trial
- Who was studied
- 8 Parkinson's disease patients with short duration L-dopa response and dyskinesias
- What was measured
- L-dopa pharmacokinetics, UPDRS, tapping speed, and dyskinesias over 4 hours
THE PAPER
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ. J Neurol Neurosurg Psychiatry, 2004.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.